Brief: Hutchmed (China) Announces NDA For Sovleplenib Accepted With Priority Review By NMPA
29/04/2026 11:47
April 29 (Reuters) - HUTCHMED (China) Ltd 0013.HK: NDA FOR SOVLEPLENIB IN WAHA ACCEPTED WITH PRIORITY REVIEW BY NMPA PHASE TRIAL FOR SOVLEPLENIB IN WAHA MET PRIMARY ENDPOINT IN JANUARY 2026 Further company coverage: 0013.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation